News
-
Scottish nebulizer developer Nebu-Flow has raised £1.7 million “to continue the commercialization and delivery of next generation respiratory pharmaceuticals,” the company has announced on social media. The funding round was led by Foresight Williams Technology.… Read more . . .
-
Zeteo Biomedical has announced the launch of its ZEOx1 OrionMRQ metered dose nasal device for delivery of drugs and vaccines. Zeteo’s ZEOx1 devices are designed for intranasal delivery of liquid formulations, and its ZEOx2 devices… Read more . . .
-
DPI developer Iconovo has announced that Galenica AB will offer cGMP manufacturing of Iconovo’s ICOone single dose disposable DPI for clinical trials, so that customers wanting to develop an inhaled drug delivered by the ICOone… Read more . . .
-
Proveris Scientific has named Ramesh Chand as Associate Director of Proveris Laboratories, the company’s contract testing business, which launched in May 2020. Chand was most recently Principal Scientist in Respiratory Drug Product Development at Moderna and previously held… Read more . . .
-
Kindeva Drug Delivery, formerly 3M Drug Delivery Systems, has announced that it will acquire inhaled drug CRO iPharma Labs, and iPharma’s team of well-known OINDP specialists will join Kindeva. Founded in 2016, iPharma extended its… Read more . . .
-
Copley Scientific has announced the launch of the Gentle Rocker 100i device for faster sample recovery from the Next Generation Impactor (NGI). According to Copley, the Gentle Rocker 100i offers controlled agitation of the entire… Read more . . .
-
CDMO Catalent, which offers services for a full range of OINDPs, has announced the completion of the first phase of “a significant expansion” of its development and manufacturing capabilities for unit dose and bi-dose nasal… Read more . . .
-
CDMO Recipharm said that it is now offering services for reformulation of MDIs with new lower global warming potential propellants such as HFA 152a and HFO 1234ze. The company also announced that it has partnered… Read more . . .
-
According to Opiant Pharmaceuticals, a pharmacodynamic study of the company’s OPNT003 intranasal nalmefene met its primary endpoint of non-inferiority compared to intranasal naloxone, with 3 mg of OPNT003 almost twice as effective as 4 mg… Read more . . .
-
Evoke Pharma announced that the FDA has granted new drug product exclusivity for Gimoti metoclopramide nasal spray, giving the company exclusive marketing rights for 3 following the initial approval date. The FDA approved Gimoti for… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.